- Joined
- Mar 1, 2012
- Messages
- 104
- Reaction score
- 11
Official 2017-2018 Rheumatology Fellowship Application Cycle
- Thread starter rheum18
- Start date
- Joined
- Mar 1, 2012
- Messages
- 104
- Reaction score
- 11
D
deleted392989
Anyone know the 3 programs that did not fill?
- Joined
- Sep 8, 2017
- Messages
- 17
- Reaction score
- 1
Rheumatology second most competitive after GI.
Matching rate for rheum 69.3%
GI 64.5%
cardio 70.5%
Hemoc 71.1%
Pul/Crit 74.5%
IMGs (foreign) only matched 18.3 % of total positions in rheumatology . This is scary for IMGs .
GI is 23.5%
Hemoc is 26.5 %
cardio is 26.4 %
So, it is definitely hardest fellowship for foreign IMGs. Sad....
Matching rate for rheum 69.3%
GI 64.5%
cardio 70.5%
Hemoc 71.1%
Pul/Crit 74.5%
IMGs (foreign) only matched 18.3 % of total positions in rheumatology . This is scary for IMGs .
GI is 23.5%
Hemoc is 26.5 %
cardio is 26.4 %
So, it is definitely hardest fellowship for foreign IMGs. Sad....
- Joined
- Oct 17, 2015
- Messages
- 448
- Reaction score
- 507
This is obviously a misinterpretation of the data. Percent match rate = competitiveness. Don't fool yourself. It is much harder to match into rheum than it used to be, and there is a clear change in the quality of applicants that the top programs get. But - it is easier to match into rheum than heme/onc, cards, etc. Even top applicants would be anxious whether they match at their first choice in heme/onc, in rheum it's still a walk.
Congrats on all of you who matched today! Well done.
- Joined
- May 26, 2016
- Messages
- 12
- Reaction score
- 7
Is it awkward to post here while going unmatched?!
Probably not.
Congratulations to all those who matched. Good luck and be the best version of yourselves.
And for those who didn’t, like me, well there is still another day. Good luck for the next year.
Probably not.
Congratulations to all those who matched. Good luck and be the best version of yourselves.
And for those who didn’t, like me, well there is still another day. Good luck for the next year.
Matched in a prestigious program! IMG, US citizen, had 10 IVs, did one year of research in rheumatology before I start my residency.
Step1 (220s), step 2 (240s), had case reports and poster presentation during residency, all in rheumatology.
They love to see you are really interested in this field and this is a field which is getting more and more competitive because of good life style.
Congrats to all who got matched and good luck for future applicants! I love this subspecialty
Step1 (220s), step 2 (240s), had case reports and poster presentation during residency, all in rheumatology.
They love to see you are really interested in this field and this is a field which is getting more and more competitive because of good life style.
Congrats to all who got matched and good luck for future applicants! I love this subspecialty
Congrats everyone who got matched in Rheumatology fellowship for 2018 intake. I am new to this forum and a future rheumatology applicant 2019 or 2020. Here are my questions:
1. What makes a potential candidate (based on this match result) USMLE scores, research papers presentations?
2. How many research papers must one have to get interviews?
3. Does huge gap between residency graduation matters?
Any advice you guys can provide to prepare my self for next year's match are really appreciated.
Thank you
1. What makes a potential candidate (based on this match result) USMLE scores, research papers presentations?
2. How many research papers must one have to get interviews?
3. Does huge gap between residency graduation matters?
Any advice you guys can provide to prepare my self for next year's match are really appreciated.
Thank you
- Joined
- Mar 1, 2012
- Messages
- 104
- Reaction score
- 11
Did you get email from program?
- Joined
- Jun 13, 2017
- Messages
- 25
- Reaction score
- 1
If you look at NRMP match data from 2013- 2017 , it clearly showed upward trending of US AMGs want rheumatology specialty more and more.
In 2014 , only 32% of total positions were filled with US AMGs. But in 2017, US AMGs took 43% of all positions. Now this year 2018, US AMGS comprised of 54.1 % of total positions in matching. This showed clearly significant upward trend of US AMGs willing to become rheumatologists.
I don't know what factors motivate them.
In 2014 , only 32% of total positions were filled with US AMGs. But in 2017, US AMGs took 43% of all positions. Now this year 2018, US AMGS comprised of 54.1 % of total positions in matching. This showed clearly significant upward trend of US AMGs willing to become rheumatologists.
I don't know what factors motivate them.
- Joined
- Sep 20, 2004
- Messages
- 6,008
- Reaction score
- 6,712
lifestyle and money...
Where does it say that AMG comprised 54.1%? I don't see the 2018 match data results
- Joined
- Jun 13, 2017
- Messages
- 25
- Reaction score
- 1
- Joined
- Jul 31, 2017
- Messages
- 29
- Reaction score
- 2
Where can we find this for other specialties
Nope
did u ?
- Joined
- Mar 1, 2012
- Messages
- 104
- Reaction score
- 11
Yes, I did.
Great! Which pgm?
- Joined
- Aug 15, 2017
- Messages
- 4
- Reaction score
- 2
Congrats to all who matched! Our final stage of training begins in July! I’m likely going to pick up the Rheum Primer, and Rheum Secrets for pleasure reading! Any other thoughts on reading material?
- Joined
- Sep 8, 2017
- Messages
- 17
- Reaction score
- 1
Time to celebrate rheumatologists. Congress passed the bill that remove 29% penalty for PART B infusion drugs. I am glad that I am rheumatology fellow now.
Will Infusion therapy era will become cash cow for rheumatologist again? Please look at ACR announcement below.
“Huge Victory for Americans Living with Rheumatic Diseases,” Says ACR President Dr. David Daikh
WASHINGTON, D.C. – The American College of Rheumatology praises Congressional leaders for passing today’s sweeping spending agreement, which includes a technical provision reversing a Centers for Medicare & Medicaid Services (CMS) policy that would have linked physicians’ quality payment adjustments to Medicare Part B drug costs starting in 2019. The ACR also applauded the inclusion of provisions that permanently repeal Medicare caps on outpatient therapies and other rehabilitation services, repeal the Independent Payment Advisory Board (IPAB), and eliminate the Medicare Part D donut hole.
“The healthcare provisions included in today’s spending agreement are a huge victory for the more than 54 million Americans living with rheumatic diseases, many of whom rely on biologic therapies and vital rehabilitation services to manage their disease,” said ACR President David Daikh, MD, PhD. “We thank Congressional leaders for coming together swiftly and in a bipartisan fashion to ensure that Americans living with diseases like rheumatoid arthritis can access the infusion therapies and rehabilitation services that help them avoid disability and maintain quality of life. This victory would not have been possible without the efforts of the many rheumatologists and rheumatology health professionals throughout the nation who voiced their concerns to lawmakers and brought attention to these incredibly important issues.”
The Part B technical correction in the spending bill comes after the ACR and more than 100 other healthcare groups urged Congressional leaders to step in and reverse course on a CMS policy that would have created extreme financial volatility for specialists who administer Part B drugs and made it more difficult for patients – particularly those living in rural and underserved areas of the country – to access physician-administered infusion therapies.
According to analysts certain specialists who administer Part B drugs – including rheumatologists, oncologists and ophthalmologists – would have seen payment cuts as high as 29 percent under the CMS policy to factor Part B drugs in MIPS payment calculations, compromising the ability of some providers to continue administering complex infusion therapies in the office setting.
The current Part B drug payment structure already makes it difficult for providers – particularly small practices and those operating in rural areas – to shoulder the financial burden of procuring and administering Part B drugs. Infusion therapies covered by the Part B program are often expensive, with few or no generic alternatives, and providers have been subjected to repeated Part B reimbursement cuts over the past decade.
“The Part B technical fix is an important course correction that will hopefully lead to productive discussions about how to realistically address the issues of care access and high drug costs,” said Daikh.
In January, an arbitrary cap was placed on Medicare outpatient therapies and other rehabilitation services 20 years after being approved in the Balanced Budget Act. Congress temporarily prevented the implementation of the caps 16 times before they began limiting access to services on January 1, 2018. A permanent repeal of these caps ends a long battle to allow Medicare patients access to the care they need based on individual circumstances.
Rheumatologists also celebrate the repeal of IPAB, the 15-member appointed board whose recommendations came with a statutorily-mandated “fast track” legislative procedure that would automatically transform IPAB proposals into law. Such recommendations had the power to impose provider cuts that could disproportionately impact small and rural practices. The ACR is relieved that such policies in the future will undergo the detailed review and deliberation of the regular legislative process.
Since 2006, eligible Medicare beneficiaries have had the option of purchasing a prescription drug benefit plan to cover medications. After meeting their deductible (which is a maximum of $400 for 2017), beneficiaries will only be responsible for 25% of the original cost of prescription drugs on their plan’s formulary. However, until changes were made in 2011, patients whose plans spent more than $3,700 found themselves in the coverage gap or “donut hole”, where they would be responsible for the full cost of their drugs until they reached an out-of-pocket threshold, which is $4,950 in 2017. After reaching the threshold, patients only paid 5% of their drug costs. The closing of this gap allows patients to access necessary medications and supports ACR's goal of access to care and our patients’ ability to adhere to carefully determined treatment plans.
“We applaud Congress for acting to protect patient access to vital therapies and services, and we look forward to working with the Administration and Congressional leaders to ensure patients living with rheumatoid arthritis and other rheumatologic conditions continue to receive innovative, medically necessary and life-sustaining care,” concluded Daikh.
Will Infusion therapy era will become cash cow for rheumatologist again? Please look at ACR announcement below.
“Huge Victory for Americans Living with Rheumatic Diseases,” Says ACR President Dr. David Daikh
WASHINGTON, D.C. – The American College of Rheumatology praises Congressional leaders for passing today’s sweeping spending agreement, which includes a technical provision reversing a Centers for Medicare & Medicaid Services (CMS) policy that would have linked physicians’ quality payment adjustments to Medicare Part B drug costs starting in 2019. The ACR also applauded the inclusion of provisions that permanently repeal Medicare caps on outpatient therapies and other rehabilitation services, repeal the Independent Payment Advisory Board (IPAB), and eliminate the Medicare Part D donut hole.
“The healthcare provisions included in today’s spending agreement are a huge victory for the more than 54 million Americans living with rheumatic diseases, many of whom rely on biologic therapies and vital rehabilitation services to manage their disease,” said ACR President David Daikh, MD, PhD. “We thank Congressional leaders for coming together swiftly and in a bipartisan fashion to ensure that Americans living with diseases like rheumatoid arthritis can access the infusion therapies and rehabilitation services that help them avoid disability and maintain quality of life. This victory would not have been possible without the efforts of the many rheumatologists and rheumatology health professionals throughout the nation who voiced their concerns to lawmakers and brought attention to these incredibly important issues.”
The Part B technical correction in the spending bill comes after the ACR and more than 100 other healthcare groups urged Congressional leaders to step in and reverse course on a CMS policy that would have created extreme financial volatility for specialists who administer Part B drugs and made it more difficult for patients – particularly those living in rural and underserved areas of the country – to access physician-administered infusion therapies.
According to analysts certain specialists who administer Part B drugs – including rheumatologists, oncologists and ophthalmologists – would have seen payment cuts as high as 29 percent under the CMS policy to factor Part B drugs in MIPS payment calculations, compromising the ability of some providers to continue administering complex infusion therapies in the office setting.
The current Part B drug payment structure already makes it difficult for providers – particularly small practices and those operating in rural areas – to shoulder the financial burden of procuring and administering Part B drugs. Infusion therapies covered by the Part B program are often expensive, with few or no generic alternatives, and providers have been subjected to repeated Part B reimbursement cuts over the past decade.
“The Part B technical fix is an important course correction that will hopefully lead to productive discussions about how to realistically address the issues of care access and high drug costs,” said Daikh.
In January, an arbitrary cap was placed on Medicare outpatient therapies and other rehabilitation services 20 years after being approved in the Balanced Budget Act. Congress temporarily prevented the implementation of the caps 16 times before they began limiting access to services on January 1, 2018. A permanent repeal of these caps ends a long battle to allow Medicare patients access to the care they need based on individual circumstances.
Rheumatologists also celebrate the repeal of IPAB, the 15-member appointed board whose recommendations came with a statutorily-mandated “fast track” legislative procedure that would automatically transform IPAB proposals into law. Such recommendations had the power to impose provider cuts that could disproportionately impact small and rural practices. The ACR is relieved that such policies in the future will undergo the detailed review and deliberation of the regular legislative process.
Since 2006, eligible Medicare beneficiaries have had the option of purchasing a prescription drug benefit plan to cover medications. After meeting their deductible (which is a maximum of $400 for 2017), beneficiaries will only be responsible for 25% of the original cost of prescription drugs on their plan’s formulary. However, until changes were made in 2011, patients whose plans spent more than $3,700 found themselves in the coverage gap or “donut hole”, where they would be responsible for the full cost of their drugs until they reached an out-of-pocket threshold, which is $4,950 in 2017. After reaching the threshold, patients only paid 5% of their drug costs. The closing of this gap allows patients to access necessary medications and supports ACR's goal of access to care and our patients’ ability to adhere to carefully determined treatment plans.
“We applaud Congress for acting to protect patient access to vital therapies and services, and we look forward to working with the Administration and Congressional leaders to ensure patients living with rheumatoid arthritis and other rheumatologic conditions continue to receive innovative, medically necessary and life-sustaining care,” concluded Daikh.
- Joined
- Oct 5, 2004
- Messages
- 555
- Reaction score
- 184
I doubt rheumatology will ever be a "cash cow" again, but more rheumatologists will probably maintain an infusion center as part of their practice than otherwise would have. If the proposed policy had gone into place I suspect a lot of rheumatologists would've just closed their infusion suite and referred patients to a hospital or megacorp infusion center like Walgreen's or others, and made up the difference by seeing more patients.
Infusion is a nice part of your overall practice revenue but the days of making a million bucks a year managing 600 stable Remicade patients are probably long gone...
Infusion is a nice part of your overall practice revenue but the days of making a million bucks a year managing 600 stable Remicade patients are probably long gone...
- Joined
- Feb 20, 2017
- Messages
- 24
- Reaction score
- 2
2018 Fellowship Acceptance Rates (# Matches / Total # Applicants):
Nephrology 94%
Infectious Disease 92%
Allergy/Immunology 87%
Endocrinology 84%
Pulm Critical Care 72%
Heme/Onc 69.5%
Cardiology 68.6%
Rheumatology 67.7%
Gastroenterology 64%
- Joined
- Oct 5, 2004
- Messages
- 555
- Reaction score
- 184
whoa.gif
This.
- Joined
- Apr 22, 2006
- Messages
- 2,794
- Reaction score
- 2,626
Well, not 600. You can still make a million managing about a 1000 Remicade patients, depending on your payer mix. If you purchase below whole sale prices for your biologics, then you can make a good chunk on each infusion.
The key going forward is having a cash business on the side. There's a lot of money in rheumatology - you just gotta have the entrepreneurial savvy.
Last edited:
- Joined
- Jun 3, 2016
- Messages
- 3
- Reaction score
- 2
I am starting out in medical school and wanted to know if there is a list of top Rheumatology Fellowship?
- Joined
- Jun 2, 2009
- Messages
- 52
- Reaction score
- 2
forgot to mention, I matched at northwell
- Joined
- Feb 8, 2015
- Messages
- 66
- Reaction score
- 45
Lol calm down tiger. Just get into a good IM program and do some research early. Youll have plenty of time to figure it out.
Similar threads
